The United Laboratories International Holdings Limited
聯邦制藥國際控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3933)

UBT251 INJECTION COMPLETED FIRST PARTICIPANT DOSING IN PHASE III CLINICAL STUDY FOR TYPE 2 DIABETES IN CHINA

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the first participant has been dosed in the Phase III clinical study in China for type 2 diabetes (the "Study") of UBT251 Injection, a Class 1 innovative drug self-developed by The United Bio-Technology (Hengqing) Co., Ltd. ("United Biotechnology"), a wholly-owned subsidiary of the Company.

This Study will consist of two separate studies, namely "UNIGUIDE-1" and "UNIGUIDE-2".

UNIGUIDE-1 adopts a randomized, double-blind, parallel, placebo-controlled trial design and is planned to enroll 360 adult participants with type 2 diabetes ($7.5\% \leq HbA_{1c} \leq 10.5\%$), with the aim of evaluating the efficacy and safety of UBT251 Injection in participants with type 2 diabetes whose glycemic control remains inadequate despite diet and exercise interventions alone. The primary endpoint of UNIGUIDE-1 is the change in HbA_{1c} from baseline after 40 weeks of treatment.

UNIGUIDE-2 adopts a randomized, open-label, parallel, semaglutide injection-controlled trial designed and is planned to enroll 956 adult participants with type 2 diabetes ($7.5\% \leq HbA_{1c} \leq 11.0\%$), with the aim of evaluating the efficacy and safety of UBT251 Injection in participants with type 2 diabetes who have inadequate glycemic control despite metformin monotherapy or combination therapy withsulfonylureas or sodium-glucose cotransporter 2 (SGLT2) inhibitors. The primary endpoint of UNIGUIDE-2 is the change from baseline in HbA_{1c} after 40 weeks of treatment. Secondary endpoints include changes in body weight, blood pressure, and blood lipid levels, as well as the change from baseline in HbA_{1c} after 52 weeks of treatment.

ABOUT UBT251

UBT251 is a long-acting triple-target receptor agonist of GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide)/GCG (glucagon). To date, the Company has been approved to conduct clinical trials in China and/or the United States for multiple indications including type 2 diabetes in adults, overweight or obesity, chronic kidney disease ("CKD"), metabolic dysfunction-associated steatohepatitis ("MASH") and moderate-to-severe obstructive sleep apnea ("OSA") with obesity. The Company is the first enterprise in China and the second globally to be approved for clinical trials of a long-acting triple agonist of GLP-1R/GIPR/GCGR prepared by chemical synthesis of polypeptide.

In March 2025, United Biotechnology and the Company entered an exclusive license agreement with Novo Nordisk A/S for UBT251.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 7 September 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.